Sergey Malitsky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sergey Malitsky has a total of 384 co-authors. Here are the top co-authors by number of shared publications:
- Ayelet Erez
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 7610001, Israel
108 shared publications - Lital N. Adler
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
106 shared publications - Emma Hajaj
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
105 shared publications - Hila Tishler
Weizmann Institute of Science 1 Department of Molecular Cell Biology Rehovot, Israel
105 shared publications - Naama Darzi
Weizmann Institute of Science 1 Department of Molecular Cell Biology Rehovot, Israel
105 shared publications - Shay Ben-Shachar
Clalit Health Services 2 Innovation Division Clalit Research Institute, Ramat Gan, Israel
105 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway
Features of chosen cell lines for DepMap analysis
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway
Features of chosen cell lines for DepMap analysis
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 10 from PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway
Characteristics of patients’ dispensing history of papaverin and statins up to 6 months prior to cancer diagnosis
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 10 from PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway
Characteristics of patients’ dispensing history of papaverin and statins up to 6 months prior to cancer diagnosis
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 11 from PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway
HR status of cancer patients used in papaverine cohort
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 11 from PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway
HR status of cancer patients used in papaverine cohort
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway
Hazard ratio (HR) status of cancer patients used in the cohort
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway
Hazard ratio (HR) status of cancer patients used in the cohort
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway
Characteristics of patients’ dispensing history of sildenafil and statins up to 6 months prior to cancer diagnosis
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway
Characteristics of patients’ dispensing history of sildenafil and statins up to 6 months prior to cancer diagnosis
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway
Characteristics of male patients’ dispensing history of sildenafil and statins up to 6 months prior to cancer diagnosis
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway
Characteristics of male patients’ dispensing history of sildenafil and statins up to 6 months prior to cancer diagnosis
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 8 from PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway
Characteristics of diabetic patients’ dispensing history of sildenafil and statins up to 6 months prior to cancer diagnosis
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 8 from PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway
Characteristics of diabetic patients’ dispensing history of sildenafil and statins up to 6 months prior to cancer diagnosis
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway
HR status of male cancer patients used in the cohort
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway
HR status of male cancer patients used in the cohort
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 9 from PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway
HR status of diabetic cancer patients used in the cohort
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 9 from PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway
HR status of diabetic cancer patients used in the cohort